Shares of Enzymotec Ltd. (NASDAQ:ENZY) have received a consensus broker rating score of 3.00 (Hold) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a hold rating. Enzymotec’s rating score has improved by 9.9% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokerages have set a twelve-month consensus target price of $10.30 for the company and are predicting that the company will post $0.08 earnings per share for the current quarter, according to Zacks. Zacks has also given Enzymotec an industry rank of 176 out of 265 based on the ratings given to its competitors.

A number of research analysts have commented on the company. Wells Fargo & Company increased their price objective on Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research report on Monday, October 30th. Jefferies Group restated a “hold” rating and issued a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Zacks Investment Research upgraded Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, ValuEngine upgraded Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th.

A number of hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in shares of Enzymotec in the 2nd quarter valued at about $2,350,000. State Street Corp raised its stake in shares of Enzymotec by 1.8% in the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 380 shares during the period. Osborn Williams & Donohoe LLC acquired a new stake in shares of Enzymotec in the 3rd quarter valued at about $137,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Enzymotec in the 3rd quarter valued at about $107,000. Hedge funds and other institutional investors own 15.73% of the company’s stock.

Shares of Enzymotec (NASDAQ:ENZY) remained flat at $$11.80 on Wednesday. 229,513 shares of the company’s stock were exchanged, compared to its average volume of 67,361. Enzymotec has a 1 year low of $5.80 and a 1 year high of $12.35.

WARNING: “Analysts Expect Enzymotec Ltd. (ENZY) to Post $0.08 EPS” was posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Get a free copy of the Zacks research report on Enzymotec (ENZY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with's FREE daily email newsletter.